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Should the dose of antituberculosis drugs be reduced in patients with
liver disease?
Patients requiring antituberculosis therapy may have underlying
liver disease. If this is associated with a reduction in functioning
cell mass as in severe acute hepatitis, chronic active liver
disease or cirrhosis, elimination of drugs which are cleared in
proportion to the functioning cell mass will be slowed, with
the risk of excessive drug accumulation and toxicity. 1 Of
particular relevance are rifampicin and isoniazid, both of
which depend largely on the liver for elimination.2 Strepto-
mycin is eliminated by the kidneys and therefore may be used
in usual doses in patients with hepatic dysfunction. Pyra-
zinamide has significant hepatotoxic potential and could be
rationally replaced by ethambutol, which is unlikely to cause
hepatotoxicity; clearance is by renal mechanisms.
Rifampicin and isoniazid are potentially hepatotoxic (hepato-
cellular necrosis and death may occur) and because increased
toxicity may be related to higher dosage and hepatic insuffi-
ciency3 (and to the use of the drugs in combination), it may
appear logical to reduce the dosage of these agents in patients
with significant liver disease. Various authors advise that
rifampicin should be used with caution or in reduced doses in
patients with impaired liver function. 1,2,4,5 The Extra Pharma-
copoeia6 advises that patients with jaundice should not be
given rifampicin, as do the manufacturers of the drug (Ciba-
Geigy - personal communication), Serum levels and half-life
of rifampicin (and isoniazid) have been shown to be significantly
higher in patients with chronic liver disease.7 This increase
appears to be small, however, and its significance with a drug
given once a day is uncertain, McConnell et al.8 found in
patients with cirrhosis that if pretreatment levels of bilirubin
exceeded 50 j.Lmol/l, there was an increase in serum rifampicin
levels after 7 days' therapy as well as a substantial increase in
bilirubin levels (±40 j.Lmol/l). The authors therefore suggested
a reduction in the rifampicin dose in cirrhotic patients whose
serum bilirubin levels exceed 50 j.Lmol/l.
With isoniazid some authors advise caution or reduction in
dose in patients with hepatic disease2,5,7 whereas others claim
that the presence of impaired liver function does not appear to
affect the kinetics and metabolism of this drug. 1,9,10
This potential risk of excessive drug accumulation and
hepatotoxicity of rifampicin (and perhaps isoniazid) with
normal dosage has to be weighed against the possibility of
inadequate treatment of severe tuberculosis or the risk of
emergence of resistance if the doses of these agents are reduced.
There is no easy solution to this problem since blood levels
cannot be routinely monitored and there is no simple guide
correlating degree of liver impairment with extent of dose
reduction.
Optimal prospective controlled long-term trials have still to
be done to provide a definite answer as to whether the dose of
rifampicin and isoniazid should be reduced in patients with
impaired hepatic function, With isoniazid the data are con-
flicting, but with rifampicin the present evidence is in favour
of exercising caution in patients with hepatic disease, especially
if significant jaundice is present. The decision whether to
reduce the dose or not may be an individual one, but it seems
prudent for all to adhere to two basic rules. Firstly, careful
and regular monitoring of liver function must be carried out
and, secondly, doses should be calculated according to body
weight in these patients, in whom there is often profound
weight loss, thus avoiding potentially too large standard adult
doses with the anendant increased risk of toxicity.
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Psychotic reactions to dopamine agonists
Psychotic reactions to high doses of bromocriptine (50 - 100
mg/d) are well known in the treatment of parkiDsonism, but
recently there have been reports of psychotic reactions asso-
ciated with the lower doses (7,5 - 30 mg/d) used to treat
acromegaly and hyperprolactinaemia. However, in earlier
reports patients usually had a history of mental instability
before treatment.
Turner et al. (Br Med] 1984; 289: 1101) now report 8 cases
out of a series of 600 patients with no psychiatric history
whatsoever who were being treated for hyperprolaetinaemia or
acromegaly. Six of the 8 were receiving bromocriptine and 2
lisuride, another dopamine agonist. Symptoms included
auditory hallucinations, delusions, and marked changes in
mood. All the reactions remined when treatment was stopped.
However, the authors emphasize that the incidence of these
reactions was very low and that the risk must be set against the
undoubted benefit of such treatment.
